Evogene Ltd.

Quarterly Report • Jul 31, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2019

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F =Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

• 99.1 Press Release: Evogene Reports Second Quarter of 2019 Financial Results.
• 99.2 A Slide Presentation for Investors July 2019.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

By: /s/ Dorit Kreiner Dorit Kreiner Chief Financial Officer

Date: July 31, 2019

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Second Quarter of 2019 Financial Results. 99.2 A Slide Presentation for Investors – July 2019.

Evogene Reports Second Quarter of 2019 Financial Results

Conference call and webcast: July 31st, 9:00 am ET

Rehovot, Israel – July 31, 2019 – Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the second quarter ending June 30, 2019.

Ofer Haviv, Evogene's President and CEO, stated: "During the first half of 2019 we completed the transition to our new corporate structure consisting of Evogene as a technology hub for multiple subsidiaries in different life-science markets. This corporate structure provides the subsidiaries with support from Evogene, to allow the subsidiaries to focus on building valuable assets and fast-tracking their product development towards commercialization. Evogene's support to its subsidiaries can be attributed to three main areas:

• Access to the CPB platform right to use the CPB platform by each subsidiary for its dedicated area of activity, to (i) advance subsidiaries' current product pipelines, (ii) to expand the subsidiaries' product pipeline.
• Corporate and infrastructure support (i) the subsidiaries' management works closely with Evogene's board, management, and advisors to benefit from their broad experience & access to industry network, (ii) Evogene provides access to its facilities and infrastructure including labs, greenhouses, and other.
• Funding Evogene intends to leverage its strong financial position to financially support its subsidiaries until a point of maturity, wherein enough valuable assets have been created to warrant an attractive valuation at fundraising, or through the generation of revenues from sales or collaborations to cover expenses. Evogene aims to remain a major shareholder in its subsidiaries following external fundraising in order to maintain, for Evogene shareholders, a significant share of the subsidiaries' future profits and/or market value.

Evogene and its subsidiaries are fully committed to achieving the milestones presented in Evogene's updated corporate presentation filed today." – Mr. Haviv concluded

Recent Developments:

• Lavie Bio announced positive 2nd year field results in its bio-stimulant program for wheat with product candidates showing repeated significant yield improvement in spring wheat field trials across multiple locations, varieties and conditions.
• Amendment of Evogene's collaboration agreement with Bayer¹ to include genome editing targets following positive results in corn stalk rot fungal disease control. Evogene will use its CPB platform to identify the required edits to improve disease resistance in corn, focusing on altering gene expression or function. Any promising targets would be pursued by Bayer's in-house team for validation.
• Evogene and certain subsidiary management have initiated a process to evaluate fundraising activities as the opportunities arise.

Consolidated financial results for the period ending June 30, 2019:

Cash position: As of June 30, 2019, Evogene had approximately \$46 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of approximately \$8.7 million during the first half of 2019 and \$4.2 million during the second quarter of 2019.

Assuming that no external financial resources are secured, such as through new collaborations or external fund raising, the Company continues to estimate that its net cash usage in 2019 will be in the range of \$16 to \$18 million dollars.

Evogene's consolidated cash use is mostly appropriated to its subsidiaries, mainly Lavie Bio, AgPlenus, and Biomica, with funds also used for the establishment of infrastructure and greenhouses for Canonic.

The Company does not have bank debts.

Revenues primarily consist of research and development payments. These revenues represent R&D cost reimbursement and milestone payments under our various collaboration agreements. The majority of these agreements also provide for royalties or other forms of revenue sharing from successfully developed products.

Gross profit for the first half of 2019 was approximately \$0.4 million in comparison to approximately \$0.2 million for the first half of 2018. Gross profit for the second quarter of 2019 remained stable at approximately \$0.1 million in comparison to the second quarter of 2018.

¹Originally with Monsanto, which was acquired by Bayer

R&D expenses for the first half of 2019 remained stable at approximately \$7 million in comparison to the first half of 2018. R&D expenses for the second quarter of 2019 remained stable at approximately \$3.5 million in comparison to the second quarter of 2018. R&D expenses mostly represent product development activities of the Company and its subsidiaries, which include field trials and pre-clinical studies provided by third parties. Evogene's consolidated R&D expenses were mostly attributed to its subsidiaries, mainly Lavie Bio, AgPlenus, and Biomica, and to its seed division activity.

Operating loss for the first half of 2019 was approximately \$9.4 million in comparison to approximately \$9.6 million in the first half of 2018. Operating loss for the second quarter of 2019 remained stable at approximately \$4.7 million in comparison to the second quarter of 2018.

Net financing income for the first half of 2019 was approximately \$1.5 million in comparison to net financing expenses of approximately \$0.5 million in the first half of 2018. Net financing income for the second quarter of 2019 was approximately \$0.6 million in comparison to net financing expenses of approximately \$0.1 million in the second quarter of 2018. This increase in the first half of 2019 is mainly due to translation of Israeli Shekel nominated cash and marketable securities to US Dollars, revaluation of the Company's marketable securities and interest income on bank deposits.

Loss for the first half of 2019 decreased to approximately to \$7.9 million in comparison to a loss of \$10.1 million during first half of 2018. Loss for the second quarter of 2019 decreased to approximately to \$4.1 million in comparison to a loss of \$4.8 million during second quarter of 2018.

Conference Call & Webcast Details:

Evogene's management will host a conference call today, the 31st of July 2019, to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888- 668-9141 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com.

A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through August 2, 2019, and an archive of the webcast will be available on the Company's website through August 11, 2019.

About Evogene Ltd.:

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies.

Today, this platform is utilized by the Company to discover and develop innovative products in the following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, human microbiome-based therapeutics and medical cannabis. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Bayer, Corteva and ICL. For more information, please visit www.evogene.com

Forward Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact: US Investor Relations:

Nir Zalik Vivian Cervantes 972-8-931-1900 646-863-6274

IR Director PCG Investor Relations IR@evogene.com vivian@pcgadvisory.com

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

	June 30, 2019			December 31, 2018
		Unaudited		Audited
CURRENT ASSETS:
Cash and cash equivalents	\$	14,097	\$	5,810
Marketable securities		9,088		26,065
Short-term bank deposits		22,592		22,592
Trade receivables		147		160
Other receivables and prepaid expenses		1,871		861
LONG-TERM ASSETS:		47,795		55,488
Long-term deposits		-		19
Operating lease right-of-use-assets		3,206		-
Property, plant and equipment, net		2,453		3,187
		5,659		3,206
	\$	53,454	\$	58,694
CURRENT LIABILITIES:
Trade payables	\$	748	\$	1,015
Employees and payroll accruals		1,735		2,095
Operating lease liability		716		-
Liabilities in respect of government grants		457		988
Deferred revenues and other advances		238		412
Other payables		819		921
		4,713		5,431
LONG-TERM LIABILITIES:
Operating lease liability		2,638		-
Liabilities in respect of government grants		3,209		2,898
Deferred revenues and other advances		9		28
Severance pay liability, net		27		31
		5,883		2,957
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.02 par value: Authorized - 150,000,000 ordinary shares; Issued and outstanding - 25,754,297 at June 30, 2019 and December 31, 2018, respectively		142		142
Share premium and other capital reserve		188,039		187,701
Accumulated deficit		(145,593)		(137,790)
Equity attributable to equity holders of the Company		42,588		50,053
Non-controlling interests		270		253
Total equity		42,858		50,306
	\$	53,454	\$	58,694

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share data)

	Six months ended	June 30,			Three months ended	June 30,		Year ended December 31,
	2019		2018		2019		2018	2018
				Unaudited				Audited
Revenues	\$ 540	\$	745	\$	192	\$	379	\$ 1,747
Cost of revenues	172		549		101		265	1,452
Gross profit	368		196		91		114	295
Operating expenses:
Research and development, net	7,024		6,945		3,480		3,460	14,686
Business development	970		1,084		477		486	2,084
General and administrative	1,746		1,786		837		841	3,514
Total operating expenses	9,740		9,815		4,794		4,787	20,284
Operating loss	(9,372)		(9,619)		(4,703)		(4,673)	(19,989)
Financing income	1,870		868		671		335	1,413
Financing expenses	(390)		(1,388)		(108)		(418)	(2,206)
Financing income (expenses), net	1,480		(520)		563		(83)	(793)
Loss before taxes on income	(7,892)		(10,139)		(4,140)		(4,756)	(20,782)
Taxes on income	3		16		1		13	30
Loss	\$ (7,895)	\$	(10,155)	\$	(4,141)	\$	(4,769)	\$ (20,812)
Attributable to:
Equity holders of the Company	\$ (7,803)		-	\$	(4,094)		-	\$ (20,758)
Non-controlling interests	(92)		-		(47)		-	(54)
	\$ (7,895)		-	\$	(4,141)		-	\$ (20,812)
Basic and diluted loss per share, attributable to equity holders of the
Company	\$ (0.31)	\$	(0.39)	\$	(0.16)	\$	(0.19)	\$ (0.81)
Weighted average number of shares used in computing basic and diluted loss per share	25,754,297		25,752,505		25,754,297		25,752,505	25,753,411

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

		Six months ended June 30,		Three months ended June 30,
	2019	2018	2019	2018	December 31, 2018
			Unaudited		Audited
Cash flows from operating activities
Loss	\$ (7,895)	\$ (10,155)	\$ (4,141)	\$ (4,769)	\$ (20,812)
Adjustments to reconcile loss to net cash used in operating activities:
Adjustments to the profit or loss items:
Depreciation	1,315	1,001	677	505	2,020
Share-based compensation	447	721	244	375	1,731
Net financing expense (income)	(1,619)	497	(608)	86	694
Taxes on income	3	16	1	13	30
	146	2,235	314	979	4,475
Changes in asset and liability items:
Decrease (increase) in trade receivables	13	3	(109)	60	(28)
Decrease (increase) in other receivables	(656)	(752)	102	(130)	95
Increase in long-term deposits	-	(2)	-	(2)	-
Increase (decrease) in trade payables	(261)	(104)	57	126	(114)
Increase (decrease) in employees and payroll accruals	(360)	(313)	45	-	(182)
Increase (decrease) in other payables	(80)	(192)	(26)	84	233
Decrease in severance pay liability, net	(4)	-	(5)	-	-
Increase (decrease) in deferred revenues and other advances	(193)	256	(135)	86	(165)
	(1,541)	(1,104)	(71)	224	(161)
Cash received (paid) during the period for:
Interest received	55	821	21	288	1,360
Taxes paid	(3)	(17)	(3)	(10)	(23)
Net cash used in operating activities	(9,238)	(8,220)	(3,880)	(3,288)	(15,161)

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Six months ended June 30,				Three months ended June 30,			Year ended December 31,
		2019		2018		2019		2018		2018
					Unaudited					Audited
Cash flows from investing activities:
Purchase of property, plant and equipment	\$	(197)	\$	(153)	\$	(114)	\$	(105)	\$	(374)
Proceeds from sale of marketable securities		19,994		21,097		13,765		13,875		63,639
Purchase of marketable securities		(1,637)		(3,155)		(1,637)		(951)		(31,700)
Proceeds from (investment in) bank deposits, net		-		1,880		-		-		(14,212)
Net cash provided by investing activities		18,160		19,669		12,014		12,819		17,353
Cash flows from financing activities:
Proceeds from exercise of options		-		9		-		-		9
Proceeds from government grants		287		153		90		96		354
Repayment of operating lease liability		(504)		-		(270)		-		-
Repayment of government grants		(575)		(44)		(546)		-		(66)
Net cash provided by (used in) financing activities		(792)		118		(726)		96		297
Exchange rate differences - cash and cash equivalent balances		157		(271)		101		(249)		(114)
Increase in cash and cash equivalents		8,287		11,296		7,509		9,378		2,375
Cash and cash equivalents, beginning of the period		5,810		3,435		6,588		5,353		3,435
Cash and cash equivalents, end of the period	\$	14,097	\$	14,731	\$	14,097	\$	14,731	\$	5,810
Significant non-cash activities
Acquisition of property, plant and equipment	\$	52	\$	81	\$	52	\$	81	\$	80

Safe Harbor Statement

This presentation contains "forward-looking to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSJR4"). Such forward-looking statements may be identified by the use of such words as "believe," "should," "planned," "estimated," "roadmap", "intential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-ocking statements due to a variety of factors, many of which are beyond Evogenes control, induding, without limitation, those described in our Periodical and Annual Reports, induding our Registration Form F-1, Annual Report on Form 20-F and in other information we file and funish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or behalf are expressly qualified in their entirety by the previous statements. Except for any obligation as required by applicable securities laws, Evogene disdaims any obligation or commitment to update any information contained in this presentation or to publicy release the results of any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not contribute a prospectus or other offering document, nor does it constitute of form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Agenda

• What we do ...
• Our technology the CPB platform
• Target markets
• Corporate structure & activities
• Summary
• Annex I: Subsidiary Overview
• Annex II: Financial Fundamentals

What We Do ...

process in life-science based markets ...

We revolutionize the product development Predictive Biology (CPB) platform

Agenda

• What we do ...
• Our technology the CPB platform
• Target markets
• Corporate structure & activities
• Summary
• Annex I: Subsidiary Overview
• Annex II: Financial Fundamentals

Evogene's Unique Product Development Approach Product Definition Candidate mainly Efficacy | Stability | Shelf-life | Shelf-life | Safety addressing the first criterion ive analysis valid: The CPB platform targeting to make it possible Increasing probability of success Reducing time to market cience Reducing budget Successful Product Launch Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at 'Stage Zero' 18

Prediction of Candidates for Life-Science Based Products

Agenda

• 트 What we do ...
• Our technology the CPB platform
• Target markets
• Corporate structure & activities
• · Summary
• Annex I: Subsidiary Overview
• Annex II: Financial Fundamentals

Targeted Markets

Biotechnology for life science industries

Agenda

• What we do ...
• Our technology the CPB platform
• Target markets
• Corporate structure & activities
• · Summary
• Annex I: Subsidiary Overview
• Annex II: Financial Fundamentals

Corporate Structure & Activities

Main Collaborations

Milestone Roadmap

agPlenus	Enter new collaboration agreement	"agPlenus	Reach 'Lead' in herbicide program
	BIOMICA Complete first pre-clinical study in oncology	BIOMICA	Enter pre-clinical trials in 2 additional programs; positive results in at least one study
	CANONIC Complete two cannabis growth cycles	CANONIC	Demonstrate first desired cannabis trait
casterra	Complete semi-commercial field trials	casterra	Enter commercial scale field trials
lavie bio	Advance product pipeline in wheat bio- stimulants	lavie bio	Complete semi-commercial trials toward 2022 commercialization
Ag seeds	Achieve non-regulated approval for genome-edited soybean products for nematodes	Ag seeds	Achieve genome-edited soybean lines for nematode resistance
Ag seeds	Achieve commercial efficacy level, in-vitro, for at least one toxin	Ag seeds	Positive results in soybean/corn for insect control trait
	2019		2020
			15

Agenda

• What we do ...
• Our technology the CPB platform
• Target markets
• Corporate structure & activities
• . Summary
• Annex I: Subsidiary Overview
• Annex II: Financial Fundamentals

Evogene at a Glance ... Summary

ORTEVA AICL

What we do:

We revolutionize the product development process in life-science based markets through the use of a unique Computational Predictive Biology (CPB) platform.

Our technology - the CPB platform:

Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at 'Stage Zero'.

CPB capabilities for prediction of innovation :

• · Genetic elements controlling desired biological processes
• · Small molecules active ingredients for chemical based products
• · Microbes active ingredients for microbial based products

Target markets and current activities:

• · Agriculture Ag-Chemicals, Seed Traits, Ag-Biologicals
• = Human Health Human Microbiome, Drug Discovery, Medical Cannabis
• · Industrial Applications Castor oil

Corporate structure: Evogene and the CPB platform at the heart of a group of subsidiaries, each focused in different life-science based markets, with exclusive access to the CPB platform for their field of activity, providing their main competitive advantage for their product development pipeline.

Main collaborations with world-leading companies :

• · Cash position \$ 46 M (June 30, 2019), no debt
• · Listed on TASE (2007) and NASDAQ (2013)

Contact: investors@evogene.com T: +972 8 931 1963

Annex I: Subsidiary Overview

Corporate Structure

Mission: design effective and sustainable crop protection products by leveraging predictive biology

Main Products under development:

Herbicides -- Market size: \$25B* (2018), growing market need for novel herbicides with improved safety profile and solution for increasing resistance to current herbicides

Insecticides - Market size: \$15B* (2018), growing market need for improved insecticide selectivity and solution for increasing resistance to current insecticides

Business Model – Delivering De-Risked Lead Candidates **agPlenus

Delivering de-risked Lead candidates targeting large multinational agrochemical companies

AgPlenus (Ag-Chemicals) - Pipeline

agPlenus

Ongoing collaborations-vote of confidence from leading Ag players

Novel herbicides - new mode of action (2016) Novel insecticides - new site of action (2018)

Novel crop enhancers development (2017)

Corporate Structure

Mission: Improve food quality, health and sustainability through the introduction of microbiome based ag-biologicals products

Products under development:

Bio-Stimulant - Market size: \$2B* (2016), Microbial based targeting yield improvement in row crops such as corn, wheat

Bio-Pesticides (Bio-Insecticides & Bio-Fungicides) - Market size: \$1.2B* (2016), Microbial based treatments, targeting insects (corn rootworm, stinkbug and lepidoptera) and fungi (fusarium and mildew)

Bio X - Microbial based consumer trait products

Lavie Bio (Ag-Biologicals) - Pipeline

Product program		Application	Discovery	Early Dev.	Dev.stage 1	Dev. stage 2	Commercial ization	Product
Bio Stimulants
Corn	Yield improvement under normal & drought	Seed treatment
Wheat	Yield improvement under normal & drought	Seed treatment
Bio Pesticides
Fusarium and seedlings disea (Corn)	Protect from Fusarium, other soil diseases and mycotoxins	Seed treatment
Mildew, Fruit rot ( focus on Grapes)	Protect from mildews and reduce chemical load	Follar
Bio X
Consumer trait A	Add consumer trait P1, P2	Foliar ,seed treatment

Corporate Structure

Mission: Bring to market top-quality seeds with high-value traits, under the "Triple S" Concept - Safe, Secure and Sustainable food

Products under development mainly via (i) GMO and (ii) Genome Editing :

Insect control traits- Lepidoptera, Coleoptera, Hemiptera

Yield and environmental stress traits- Yield, drought, nitrogen usage efficiency

Disease resistance traits- Fusarium, Black Sigatoka, Asian Rust, Nematodes

• (i) GMO genetically modified organism: an organism whose genetic material has been altered by means of genetic engineering
• (ii) Genome Editing edits made to the existing genome

Discover & develop novel proteins conferring resistance to key insects through new modes of action

Crop	Insect order	Major Pest	Discovery		Phase I POC & MoA	Phase II Early Dev.	Market size\$
Crop	Insect order	Major Pest	Discovery D1 D2	Optimization & MoA P1	Target Plant Active P2	Target Plant Lead_ p3	Market size\$
	Hemipteran	Southern green stinkbug					~1.38
Soybean		Fall armyworm
	Lepidopteran	Cotton bollworm (H. armigera)					~1B\$
	Coleopteran	Western corn rootworm					~1.2B\$
Corn	Lepidopteran	Fall armyworm
		Corn earworm					~2.16B\$
Cotton	Lepidoptera	Pink bollworm Fall armyworm	\$ 111 12 mt				~0.95B\$
	Coleopteran	Cotton boll weevil					TBD

Diverse trait portfolio with novel Mode of Action !

| 30

Insect Control - Example

Confirmed protection from Southern Green Stinkbug (STK) in transgenic tomato in 3 experiments

Yield and Environmental Stress Product Candidates*

			18m-24m	4-6 year	2-4 year	1-2 years	1-2 years
Crop	Trait	Partner	Discovery	Phase 1 (РОС)	Phase 2 (Early Development)	Phase 3 (Adv. Dev& Regulation)	Phase IV (Pre-Launch)	Product
Corn	Yield	DAYER
	Drought
	Nitrogen use efficiency	BAYER
Soybean	Yield
	Drought	AYEI

*Timeline accordingto industry estimates
**Collaborationswith Bayer, were previously initiated with Monsanto

Yield and Environmental Stress Collaboration Example Bayer (Monsanto)

• Collaboration period 10 years
• · Objective improved seeds via biotechnology
• Crops corn, soybean, cotton, canola
• Traits (i) Yield/drought tolerance/fertilizer utilization

(II) Fusarium resistance in corn

· Key terms -

• R&D and up-front payments total ~\$68M
• Milestone payments + royalties from sales

Development and commercialization

■ \$30M equity investment

Gene discovery and trait optimization

СРВ

Model plant
validation

Target plant validation

Improved seeds

Disease Resistance Pipeline:

	Disease Resistance GMO Product Candidates: *
			18m-24m	4-6 year	2-4 year	1-2 years	1-2 years
Crop	Trait	Partner	Discovery	Phase 1 (РОС)	Phase 2 (Early Development)	Phase 3 (Adv. Dev& Regulation)	Phase IV (Pre -Launch)	Product
Corn	Fusarium stalk rot	(BAYER)
Soybean	Asian Rust	CORTEVA
Banana	Black Sigatoka	RA ANUERSIEN I RRIDI ANGAL

Genome Editing Disease Resistance Product Candidates:

			6m-12m	1-2 year	1-2 year	3-4 years
Crop	Trait	Partner	Discovery	Phase 1 (Creation of Edits)	Phase 2 (Field Testing)	Phase 3 (Seed Production)	Product
Banana	Black Sigatoka	EL SURFRONT
Soybean	Nematode	тямь
Corn	Fusarium stalk rot	6

*Timeline accordingto industry estimates
**Collaborationswith Bayer, were previously initiated with Monsanto

Genome Editing Disease Resistance Example

Evogene Amends its Collaboration Agreement with Bayer to Include Genome Editing Targets

Amended agreement follows positive results in corn stalk rot fungal disease control

Rehovot, Israel - July 16, 2019 - Evogene Ltd. (NASDAQ, TASE: EVGN) a leading biotechnology company developing novel products for life science markets, announces today that after achieving positive results, its corn disease resistance research collaboration with the Crop Science Division of Bayer1 is being refocused on the identification of genome editing targets for evaluation against a broad range of corn diseases. Evogene will use its CPB (Computational Predictive Biology) platform to identify the required edits to improve disease resistance in corn. The edits will be based on Evogene-discovered genes and the accumulated knowledge achieved through this collaboration, focusing on altering gene expression or function. Any promising targets would be pursued by Bayer's in-house team for validation.

Corporate Structure

Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology

Products under development:

Microbiome and small molecule based therapies for:

• Immuno-oncology (with ICI) combination therapy for cancer
• MDRO (Multi Drug resistant organisms) targeting antibiotic resistant bacteria
• GI related disorders GI inflammatory & functional disorders

Big Biopharma is Investing More Through Partnerships

			Janssen			lakeda
SECOND GENOME		VEDANTA	SECOND GENOME enterome		enterome	FINCH	NUBIYOTA
Obesity and metabolic disease		Inflammatory bowel disease	Ulcerative Colitis	Crohn's disease	Inflammatory bowel disease	Inflammatory bowel disease	Gastrointestinal indications
2014		2013	2013	2016	2016	2017	2017
abbvie			Allergan		Bristol-Myers Squibb	MERCK
enterome	synlogic		(A) assembly		enterome
disease	Crohn's Inflammatory bowel disease		Inflammatory bowel disease		Immunoocncology		Immunoocncology
2014	2016		2016 2017			2018
	Genentech microblotica Inflammatory bowel disease		novo nordisk KALLYOPE Obesity and diabetes		SERES C. Ddiff, inflanim, bowel disease	Nestle enterome Diagnostics
	2018		2018		2016	2017	1 38

Pipeline

	Program	Indication / Target	Discovery	Preclinical	Phase 1	Phase 2	Approach
Immuno- oncology (with ICI)	BMC121	Combination Therapy for NSCLC
	BMC127	Combination Therapy for NSCLC
MDRO	BMC201	C. difficile toxin-B
	BMC426	IBS
GI related disorders	BMC321	IBD
	BMC322	IBD

Small Molecule

Corporate Structure

Canonic - Mission & Products

Mission: To develop and bring to market medical grade cannabis through a revolutionary genomic approach

Products under development:

• · MetaYield* Increased metabolite yield
• · Unican* Verified variety stability
• · Precise* Tailored metabolite profiles targeting:
  • Chronic pain .
  • · PTSD Post traumatic stress disorder
  • Cancer care .

* Finalized product names to be determined

Innovative products to address key market needs:

Milestone Roadmap

Corporate Structure

casterra

Our mission: Providing stable supply for the growing market demand for castor oil

Product:

An integrated ag-solution for castor - proprietary castor seed varieties supported by novel agrotechnical know-how and proprietary mechanical harvesting.

Revenue sharing with oil producers

Seed sales - Integrated solution (inc. growth protocol & mechanical harvest)

Pipeline

casterra

Annex II: Financial Fundamentals

Thousand US \$	30.06.2019	31.12.2018
Current Assets	47,795	55,488
Long-Term Assets	5,659	3,206
Total Assets	53,454	58,694
Current Liabilities	4,713	5,431
Long-Term Liabilities	5,883	2,957
Total Shareholders Equity	42,858 50,306
Total Liabilities & Shareholders Equity	53,454	58,694

• Cash position: ~46 million USD as of 30.06.2019
• No debt ■
• · Estimated net cash usage for 2019: \$16-\$18 million
• Listed on TASE (2007) and NASDAQ (2013)

evogene

Key Financials - P&L

Thousand US \$	H1 2019	H1 2018	Q2 2019	Q2 2018	2018
Revenues	540	745	192	379	1,747
Gross Profit	368	196	91	114	295
Operating Loss	(9,372)	(9,619)	(4,703)	(4,673)	(19,989)
Loss	(7,895)	(10,155)	(4,141)	(4,769)	(20,812)